240.50
-0.08%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Matricelf
Its shares trade on Tel Aviv under the ticker MTLF.TA. It has been listed since 20 June 2021.
Matricelf Ltd. is a biotechnology company, which engages in research and development of a platform for autologous matrix and cell implants in the field of regenerative medicine and tissue engineering. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jun 2021
- Website
- matricelf.com ↗
Leadership
Pay as last reported
- Mr. Doron BirgerChairman of the Board, since 2020
- Mr. Asaf TokerChief Executive Officer, General ManagerILS 1.8m
- Mr. Sigal RousseauChief Financial Officer
- Mr. Tal DvirChief Scientific Officer, Director, since 2019ILS 1.7m
- Mr. Sinai AlonVice President - Operations, since 2019ILS 831,000
- Ms. Tamar Harel AdarVice President - Research and DevelopmentILS 533,000
- Mr. Chinese OakDeputy General Director, Director, since 2019
- Mr. Tal Ben NariaOperations Manager
- Ms. Ruth ArnonIndependent Director
- Mr. Uri HershkovichIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Matricelf Ltd. develops autologous matrix and cell implants for regenerative medicine using patient-derived cellular components.
- The company focuses on spinal cord injury treatment with additional development for myocardial infarction and Parkinson's disease.
- Matricelf Ltd. is a spin-out from Tel Aviv University, leveraging academic research for biotechnology innovation.
Weaknesses
- The company operates in a highly competitive biotechnology sector with significant R&D costs.
- Limited commercialization of products beyond spinal cord injury treatment in regenerative medicine.
- Dependence on academic partnerships for initial research and development efforts.
Opportunities
- Expansion into additional medical conditions like age-related macular degeneration and myocardial infarction.
- Growing global demand for regenerative medicine solutions in the Health Care sector.
- Potential partnerships with healthcare providers in Israel and international markets.
Threats
- Regulatory challenges in biotechnology product approvals across different countries.
- High costs associated with clinical trials for new medical treatments.
- Competition from established biotechnology firms in the Health Care industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.